Ruangkanchanasetr Rawee, Lee John Y K, Nagda Suneel N, Geiger Geoffrey A, Kolker James D, Bigelow Douglas C, Ruckenstein Michael J, Nasrallah MacLean, Alonso-Basanta Michelle
Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand.
Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
J Neurol Surg B Skull Base. 2018 Dec;79(6):580-585. doi: 10.1055/s-0038-1651504. Epub 2018 May 10.
Gamma Knife stereotactic radiosurgery (GK-SRS) is a preferred treatment option for tumors of the jugular foramen. We hypothesized that GK-SRS toxicity is higher for lower cranial nerve schwannomas than for glomus jugulare tumors despite anatomically similar locations. We performed a retrospective review of all patients who received GK-SRS for glomus jugulare tumors and lower cranial nerve schwannomas at our institution between 2006 and 2014. Because of small sample sizes, Fisher's exact tests and logistic regression techniques were employed using SPSS. We identified 20 glomus jugulare tumors and 6 lower cranial nerve schwannoma patients with a median follow-up of 17 months. Median marginal dose was 16 Gy (range 13-18 Gy) and 12.5 Gy (range 12-14 Gy), respectively. All except one patient had tumor control at last follow-up visit. No worsening of pre-existing neurological deficits was observed. There were seven patients who developed any new neurological deficit after GK-SRS, four from the glomus group, and three from the schwannoma group (20 and 50% of each group, respectively). Only two of seven patients had permanent new neurological deficits. Both of them were in the schwannoma group. Univariate analysis showed that only a diagnosis of schwannoma had a greater risk of permanent new cranial nerve complication after GK-SRS compared with diagnosis of glomus jugulare ( = 0.046). Although the marginal dose for glomus jugulare is greater, our study suggests that the risk of a new permanent neurological deficit after GK-SRS was higher in the schwannoma group compared with the glomus group.
伽玛刀立体定向放射外科治疗(GK-SRS)是颈静脉孔区肿瘤的首选治疗方案。我们推测,尽管下颅神经鞘瘤和颈静脉球瘤在解剖位置上相似,但GK-SRS对下颅神经鞘瘤的毒性高于颈静脉球瘤。
我们对2006年至2014年间在本机构接受GK-SRS治疗的颈静脉球瘤和下颅神经鞘瘤患者进行了回顾性研究。由于样本量较小,使用SPSS软件进行Fisher精确检验和逻辑回归分析。
我们确定了20例颈静脉球瘤患者和6例下颅神经鞘瘤患者,中位随访时间为17个月。中位边缘剂量分别为16 Gy(范围13 - 18 Gy)和12.5 Gy(范围12 - 14 Gy)。除1例患者外,所有患者在最后一次随访时肿瘤均得到控制。未观察到原有神经功能缺损恶化。有7例患者在GK-SRS后出现任何新的神经功能缺损,颈静脉球瘤组4例,神经鞘瘤组3例(分别占每组的20%和50%)。7例患者中只有2例出现永久性新的神经功能缺损,均在神经鞘瘤组。单因素分析显示,与颈静脉球瘤诊断相比,神经鞘瘤诊断在GK-SRS后发生永久性新的颅神经并发症的风险更高(P = 0.046)。
尽管颈静脉球瘤的边缘剂量更大,但我们的研究表明,与颈静脉球瘤组相比,神经鞘瘤组在GK-SRS后出现新的永久性神经功能缺损的风险更高。